Programme 2020
Friday: September 11, 2020
10:00 (EST)
Introduction & Virtual Meeting Objectives
John Gribben
10:05-10:55
Session I: Hodgkin’s Lymphoma
Chair: Peter Johnson & Pier Luigi Zinzani
- Early-stage unfavorable cHL; Peter Borchmann
- KEYNOTE 204; Pier Luigi Zinzani
- Hodgkin’s Lymphoma in the era of targeted therapy; Peter Johnson / Amin Islam
Roundtable Discussion
10:55-11:45
Session II: Immunotherapy/Microenvironment
Chair: David Maloney & Stephen Ansell
- Crosstalk between lymphocytes and their microenvironment; Patricia Pérez Galán
- PRAME expression and the tumour microenvironment; David Scott
- CBT in specific lymphoma subtypes; Stephen Ansell
Roundtable Discussion
11:45-12:35
Session III: Novel Therapies Part I
Chairs: Laurie Sehn & Franck Morschhauser
- Novel ADCs; Laurie Sehn
- CD20 / CD3 bispecific antibodies: How to choose?; Franck Morschhauser
- Oral PI3K delta (δ) inhibitors in lymphoma;
Roundtable Discussion
12:35-15:00
Roundup of Day 1:
John Gribben, Stephen Ansell, Laurie Sehn & Franck Morschhauser
Saturday: September 12, 2020
10:00-10:55
Session IV: Novel Therapies Part II
- Novel BTK inhibitors: how to choose?; Tom Witzig
- SINE inhibitors: Selinexor; Sundar Jagannath
- Tafasitamab (MOR208) in DLBCL; Gilles Salles
Roundtable Discussion
10:55-11:45
Session V: T-cell Therapies for Lymphoma
Chairs: Cath Bollard & Jeremy Abramson
- CD19-CAR-T cells; Jeremy Abramson
- CD30, CD5 and/or 7 CAR-T cells; Cath Bollard
- T cell-engaging therapies – BiTEs and beyond; Ralf C. Bargou
Roundtable Discussion
11:45-12:00
Final Virtual Meeting Summary & Conclusions
iwNHL Scientific Committee
